PF-00547659 SC injection

DRUG2 trials

Conditions

Crohn's DiseaseUlcerative Colitis

Phase 2

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

CompletedNCT01276509

ShireCrohn's Disease

Start: 2011-04-06End: 2015-10-09Updated: 2021-06-03

A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

CompletedNCT01620255

ShireUlcerative Colitis

Start: 2012-11-02End: 2016-02-04Updated: 2021-06-11

Journal of Crohn s and Colitis2023-08-243 citations

Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study

Inflammatory Bowel Diseases2021-08-2416 citations

Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II

Journal of Crohn s and Colitis2021-02-1533 citations

Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study

Intestinal Research2020-01-3010 citations

P069 ONTAMALIMAB, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1, PROVIDES SUSTAINED EXPOSURE FOLLOWING LONG-TERM TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Inflammatory Bowel Diseases2020-01-01

P081 Rapid Symptomatic Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From TURANDOT and TURANDOT II

The American Journal of Gastroenterology2019-12-01

P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II)

Inflammatory Bowel Diseases2019-02-014 citations

P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY

Inflammatory Bowel Diseases2019-02-01

OP08 Long-term efficacy and pharmacodynamics of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) monoclonal antibody SHP647 in Crohn’s disease: the OPERA II study

Journal of Crohn s and Colitis2019-01-253 citations

Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers

Journal of Crohn s and Colitis2019-01-1020 citations

Long-Term Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Antibody SHP647 in Ulcerative Colitis: An Open-Label Extension Study (TURANDOT II)

The American Journal of Gastroenterology2018-10-01

Population Pharmacokinetics and Pharmacodynamics of SHP647, a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule-1 (anti-MAdCAM-1), in Patients With Ulcerative Colitis or Crohnʼs Disease

The American Journal of Gastroenterology2018-10-01

Long-Term Safety, Efficacy and Pharmacokinetics of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Monoclonal Antibody SHP647 in Crohnʼs Disease: The OPERA II Study

The American Journal of Gastroenterology2018-10-01

DOP062 The anti-MAdCAM antibody SHP647 in Crohn’s disease: Endoscopic effects of induction therapy

Journal of Crohn s and Colitis2018-01-162 citations

P735 Incidence of venous thromboembolic complications in controlled trials of inflammatory bowel disease

Journal of Crohn s and Colitis2018-01-16

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study

Gut2017-10-05107 citations

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.

2017-05-17131 citations

PF-00547659 SC injection

Sponsors

Conditions

Phase 2

Related Papers